Jul. 15 at 11:06 AM
$CADL Candel's M & A focus is meticulous & assured BLA submission, but Dr. PPT has already acknowledged that they have been approached by big pharma. Candel's pipeline is a trophy asset.
AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to
$1.5B
AstraZeneca is pledging up to
$1.5 billion to link up with China’s Dizal Pharmaceutical, securing an exclusive worldwide license to the oral lung cancer drug Zegfrovy. This is the U.K. pharma’s third agreement inked with an Asian company this month. AstraZeneca is committing
$600 million upfront and earmarking up to
$900 million in development, regulatory and sales-related milestones
https://www.biospace.com/deals/astrazeneca-takes-another-china-trip-picking-dizals-lung-cancer-drug-for-up-to-1-5b
